Inhibition of Angiogenesis: Treatment Options for Patients with Metastatic Prostate Cancer

Greenlee RT, Murray T, Bolden S, Wingo PA: Cancer statistics, 1999. CA Cancer J Clin 50: 7–33, 2000 Folkman, J: Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182–1186, 1971 Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353–364, 1996 Weidner N, Semple JP, Welch WR, Folkman J: Tumor angiogenesis and metastasis - Correlation in invasive breast carcinoma. New Engl J Med 324: 1–8, 1991 St Croix B, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E, Lal A, Riggins GJ, Lengauer C, Vogelstein B, Kinzler KW: Genes expressed in human tumor endothelium Science 289: 1197–1202, 2000 Dirix LY, Vermeulen PB, Pawinski A: Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in the sera of cancer patients British J Cancer 76(2): 238–243, 1997 Colomer R, Apricio J, Montero S, Guzman C, Larrodera L, Cortes-Funes H: Low levels of basic fibroblast growth factor (bFGF) are associated with a poor prognosis in human breast carcinoma. British J Cancer 76(9): 1215–1220, 1997 Li VW, Folkerth RD, Watanabe H, Yu C, Rupnich M, Barnes P, Scott RM, Black PM, Sallan SE, Folkman J: Microvessel count and cerebrospinal fluid basic fibroblast growth factor in children with brain tumors. Lancet 344: 82–86, 1994 Nguyen M, Watanabe H, Budson E, Richie JP, Hayes DF, Folkman J: Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst 86(5): 356–361, 1994 Takahashi Y, Bucana CD, Liu W, Yoneda J, Kitadai Y, Cleary KR, Ellis LM Platelet-derived endothelial cell growth factor in human colon cancer angiogenesis: role of infiltrating cells. J Natl Cancer Inst. 21;88(16): 1146–1151, 1996 Strohmeyer D, Rossing C, Strauss F, Bauerfeind A, Kaufmann O, Loening S: Tumor angiogenesis is associated with progression after radical prostatectomy in pT2/pT3 prostate cancer. Prostate 42(1): 26–33, 2000 Lissbrant IF, Stattin P, Damber JE, Bergh A. Vascular density is a predictor of cancer-specific survivalin prostatic carcinoma. Prostate 15;33(1): 38–45, 1997 Krupski T, Petroni GR, Frierson HF Jr, Theodorescu JU. Microvessel density, p53, retinoblastoma, and chromogranin A immunohistochemistry as predictors of disease-specific survival following radical prostatectomy for carcinoma of the prostate. Urology 55(5): 743–749, 2000 Gettman MT, Pacelli A, Slezak J, Bergstralh EJ, Blute M, Zincke H, Bostwick DG: Role of microvessel density in predicting recurrence in pathologic Stage T3 prostatic adenocarcinoma. Urology 54(3): 479–485, 1999 Rubin MA, Buyyounouski M, Bagiella E, Sharir S, Neugut A, Benson M, de la Taille A, Katz AE, Olsson CA, Ennis RD: Urology. 53(3): 542–547, 1999 De la Taille A, Katz AE, Bagiella E, Buttyan R, Sharir S, Olsson CA, Burchardt T, Ennis RD, Rubin MA: Microvessel density as a predictor of PSA recurrence after radical prostatectomy. A comparison of CD34 and CD31. Am J Clin Pathol 113(4): 555–562, 2000 Sipkins DA, Cheresh DA, Kazemi MR, Nevi LM, Bednarski MD, Li KCP: Detection of tumor angiogenesis in vivo by alpha-v beta-3-targeted magnetic resonance imaging. Nature Med 4(5): 623–626, 1998 Jain RK, Schlenger K, Hockel M: Quantitative angiogenesis assays: progress and problems. Nature Med 3: 1203–1208, 1997 Kurdziel K, Bacharach S, Carrasquillo J, Huebsch S, Whatley M, Sellers D, Steinberg S, Libutti S, Pluda J, Reed E, Dahut W, Figg W: Using PET 18F-FDG, 11CO, and 15O-water for Monitoring Prostate Cancer During a Phase II Anti-angiogenic Drug Trial with Thalidomide. Clin Positron Imaging 3(4): 144, 2000 Parangi S, O'Reilly M, Christofori G, Holmgren L, Grosfeld J, Folkman J, Hanahan D: Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc Natl Acad Sci USA 93: 2002–2007, 1996 Singh Y, Shikata N, Kiyozuka Y, Nambu H, Morimoto J, Kurebayashi J, Hioki K, Tsubura A: Inhibition of tumor growth and metastasis by angiogenesis inhibitor TNP-470 on breast cancer cells lines in vitro and in vivo. Breast Canc Res Treat 45: 15–27, 1997 Yanase T, Tamura M, Fujita K, Kodama S, Tanaka K: Inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of human cell lines in vitro and in vivo. Cancer Res 53: 2566–2570, 1993 Hama Y, Fujimori M, Usuda N, Nakagawara A, Amano J: Therapeutic efficacy of the angiogenesis inhibitor O-(chloroacetyl-carbamoyl) fumagillol (TNP-470; AGM-1470) for human anaplastic thyroid carcinoma in nude mice. Proc Am Assoc Cancer Res 370 397, 1996 Kato T, Sato K, Kakinuma H, Matsuda Y: Enhanced suppression of tumor growth by combination of angiogenesis inhibitor o-(chloroacetyl-carbamoyl)fumagillol (TNP-470) and cytotoxic agents in mice. Cancer Res 54: 5143–5147, 1994 Teicher BA, Sotomayor EA, Huang ZD: Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res 52: 6702–6704, 1992 Abe J, Zhou W, Takuwa N, Taguchi J, Kurokawa K, Kumada M, Takuwa Y: A fumagillin derivative angiogenesis, AGM-1470, inhibits activation of cyclin-dependent kinases and phosphorylation of retinoblastoma gene product but not protein tyrosyl phosphorylation of protooncogene expression in vascular endothelial cells. Cancer Res 54: 3407–3412, 1994 Hori A, Ikeyama S, Sudo K: Suppression of cyclin d1mRNA expression by the angiogenesis inhibitor TNP-470 (AGM-1470) in vascular endothelial cells. Biochem Biophy Res Commun 204: 1067–1073, 1994 Sin N, Meng L, Wang MQ, Wen JJ, Bornmann WG, Crews CM: The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc Natl Acad Sci USA 94(12): 6099–6103, 1997 Turk BE, Griffith EC, Wolf S, Biemann K, Chang YH, Liu JO: Selective inhibition of amino-terminal methionine processing by TNP-470 and ovalicin in endothelial cells. Chem Biol 6: 823–833, 1999 Dezube BJ, Von Roenn JH, Holden-Wiltse J, Cheung TW, Remick SC, Cooley TP, Moore J, Sommadossi JP, Shriver SL, Suckow CW, Gill PS: Fumagillin analog in the treatment of Kaposi's sarcoma: a phase I AIDS Clinical Trial Group study. AIDS Clinical Trial Group No. 215 Team. J Clin Oncol. 16(4): 1444–1449, 1998 Stadler WM, Kuzel T, Shapiro C, Sosman J, Clark J, Vogelzang NJ: Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma. J Clin Oncol 17(8): 2541–2545, 1999 Bhargava P, Marshall JL, Rizvi N, Dahut W, Yoe J, Figuera M, Phipps K, Ong VS, Kato A, Hawkins MJ: A Phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer. Clin Cancer Res 5(8): 1989–1995, 1999 Kudelka AP, Levy T, Verschraegen CF, Edwards CL, Piamsomboon S, Termrungruanglert W, Freedman RS, Kaplan AL, Kieback DG, Meyers CA, Jaeckle KA, Loyer E, Steger M, Mante R, Mavligit G, Killian A, Tang RA, Gutterman JU, Kavanagh JJ: A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix. Clin Cancer Res 3(9): 1501–1505, 1997 Zukiwski A, Gutterman J, Bui C, Sella A, Ellerhorst J, Tu S, Amato R, Figg W, Kilbourn R, Logothetis C: Phase I trial of angiogenesis inhibitor TNP-470 (AGM-1470) in patients with androgen-independent prostate cancer. Proc Am Soc Clin Oncol 13: A7495, 1994 Horti J, Dixon SC, Logothetis CJ, Guo Y, Reed E, Figg WD: Increased transcriptional activity of prostate-specific antigen in the presence of TNP-470, an angiogenesis inhibitor. Br J Cancer 79(9-10): 1588–1593, 1999 Lenz W: Thalidomide and congenital abnormalities. Lancet i: 45, 1962 McBride WG: Thalidomide and congenital abnormalities. Lancet ii: 1358, 1961 D'Amato RJ, Loughnan MS, Flynn E, Folkman J: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91: 4082–4085, 1994 Bauer KS, Dixon SC, Figg WD: Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem Pharmacol 1;55(11): 1827–1834, 1998 Baidas SM, Winer EP, Fleming GF, Harris L, Pluda JM, Crawford JG, Yamauchi H, Isaacs C, Hanfelt J, Tefft M, Flockhart D, Johnson MD, Hawkins MJ, Lippman ME, Hayes DF: Phase II evaluation of thalidomide in patients with metastatic breast cancer. J Clin Oncol 18(14): 2710–2717, 2000 Little RF, Wyvill KM, Pluda JM, Welles L, Marshall V, Figg WD, Newcomb FM, Tosato G, Feigal E, Steinberg SM, Whitby D, Goedert JJ, Yarchoan R: Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin Oncol 18(13): 2593–2602, 2000 Eisen T, Boshoff C, Mak I, Sapunar F, Vaughan MM, Pyle L, Johnston SR, Ahern R, Smith IE, Gore ME: Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 82(4): 812–817, 2000 Fine HA, Figg WD, Jaeckle K, Wen PY, Kyritsis AP, Loeffler JS, Levin VA, Black PM, Kaplan R, Pluda JM, Yung WK: Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 18(4): 708–715, 2000 Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 18;341(21): 1565–1571, 1999 Figg WD, Dahut W, Duray P, Hamilton M, Tompkins A, Steinberg SM, Jones E, Premkumar A, Linehan WM, Floeter MK, Chen CC, Dixon S, Kohler DR, Kruger EA, Gubish E, Pluda JM, Reed E: A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Canc Res 2001 (in press) Cooper PR: Investigator's Brochure for CC5013. Celgene Corporation 1–38, 2000 Hupe DJ, Boltz R, Cohen CJ, Felix J, Ham E, Miller D, Soderman D, Van Skiver D: The inhibition of receptor-mediated and voltage-dependent calcium entry by the anti-proliferative L-651,582. J Biol Chem 266: 10136–10142, 1991 Hupe DJ, Behrens ND, Boltz R: Anti-proliferative activity of L-651,582 correlates with calcium-mediated regulation of nucleotide metabolism at phosphoribosyl pyrophosphate synthetase. J Cell Physio 144: 457–466, 1990 Kohn EC, Liotta LA: L651582: A novel anti-proliferative and anti-metastasis agent. J Natl Canc Inst 82: 54–60, 1990 Wasilenko WJ, Palad AJ, Somers KD, Blackmore PF, Kohn EC, Rhim JS, Wright GL, Schellhammer PF: Effects of the calcium influx inhibitor carboxyamido-triazole on the proliferation and invasiveness of human prostate tumor cell lines. Intl J Cancer 68: 259–264, 1996 Lambert PA, Somers KD, Kohn EC, Perry RR: Antiproliferative and antiinvasive effects of carboxyamido-triazole on breast cancer cell lines. Surgery 122: 372–379, 1997 Jacobs W, Mikkelsen T, Smith R, Nelson K, Rosenblum ML, Kohn EC: Inhibitory effects of CAI in glioblastoma growth and invasion. J Neuro-Oncol 32: 93–101, 1997 Kohn EC, Alessandro R, Spoonster J, Wersto RP, Liotta LA: Angiogenesis: role of calcium-mediated signal transduction. Proc Natl Acad Sci USA 92: 1307–1311, 1995 Kohn EC, Jacobs W, Kim YS, Alessandro R, Stetler-Stevenson WG, Liotta LA: Calcium influx modulates expression of matrix metalloproteinase-2 (72-kDa type IV collagenase, gelatinase A). J Biol Chem 269: 21505–21511, 1994 Kohn EC, Reed E, Sarosy G, Christian M, Link CJ, Cole K, Figg WD, Davis PA, Jacob J, Goldspiel B, Liotta LA: Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers. Cancer Res 1;56(3): 569–573, 1996 Berlin J, Tutsch KD, Hutson P, Cleary J, Rago RP, Arzoomanian RZ, Alberti D, Feierabend C, Wilding G: Phase I clinical and pharmacokinetic study of oral carboxyamidotriazole, a signal transduction inhibitor. J Clin Oncol 15(2): 781–789, 1997 Kohn EC, Figg WD, Sarosy GA, Bauer KS, Davis PA, Soltis MJ, Thompkins A, Liotta LA, Reed E: Phase I trial of micronized formulation carboxyamidotriazole in patients with refractory solid tumors: pharmacokinetics, clinical outcome, and comparison of formulations. J Clin Oncol 15(5): 1985–1993, 1997 Bauer KS, Figg WD, Hamilton JM, Jones EC, Premkumar A, Steinberg SM, Dyer V, Linehan WM, Pluda JM, Reed E: A pharmacokinetically guided Phase II study of carboxyamidotriazole in androgen-independent prostate cancer. Clin Cancer Res 5(9): 2324–2329, 1999 O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277–285, 1997 Oh SP, Kamagata Y, Muragaki Y, Timmons S, Ooshima A, Olsen BR: Isolation and sequencing of cDNAs for proteins with multiple domains of Gly-Xaa-Yaa repeats identify a distinct family of collagenous proteins. Proc Natl Acad Sci USA 91, 4229–4233, 1994 Boehm T, Folkman J, Browder T, O'Reilly MS: Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390, 404–407, 1997 Yokoyama Y, Dhanabal M, Griffioen AW, Sukhatme VP, Ramakrishnan S: Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth. Cancer Research 60, 2190–2196, 2000 Felbor U, Dreier L, Bryant RAR, Ploegh HL, Olsen BR, Mothes W: Secreted cathepsin L generates endostatin from collagen XVIII. EMBO J 19, 1187–1194, 2000 Zatterstrom UK, Felbor U, Fukai N, Olsen BR: Collagen XVIII/endostatin structure and functional role in angiogenesis. Cell Struc Func 25, 97–101, 2000 Dhanabal M, Ramchandran R, Waterman MJF, Lu H, Knebelmann B, Segal M, Sukhatme VP: Endostatin induces endothelial cell apoptosis. J Biol Chem 274, 11721–11726, 1990 Dhanabal M, Volk R, Ramchandran R, Simons M, Sukhatme VP: Cloning, expression, and in vitro activity of human endostatin. Biochem Biophy Res Comm 258, 345–352, 1999 Kruger EA, Duray PH, Tsokos MG, Venzon DJ, Libutti SK, Dixon SC, Rudek MA, Pluda J, Allegra C, Figg WD: Endostatin inhibits microvessel formation in the ex vivo rat aortic ring angiogenesis assay. Biochem Biophy Res Comm 268, 183–191, 2000 Dixelius J, Larsson H, Sasaki T, Holmqvist K, Lu L, Engstrom A, Timpl R, Welsh M, Claesson-Welsh L: Endostatin-induced tyrosine kinase signaling through the Shb adaptor protein regulates endothelial cell apoptosis. Blood 95, 3403–3411, 2000 Kim Y-M, Jang J-W, Lee O-H, Yeon J, Choi E-Y, Kim KW, Lee S-T, Kwon Y-G: Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. Cancer Research 60, 5410–5413, 2000 Fong TAT, Shawver LK, Sun L: SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 59: 99–106, 1999 Laird AD, Vajkoczy P, Shawver LK, Thurnher A, Liang C, Mohammadi M, Schlessinger J, Ullrich A, Hubbard SR, Blake RA, Fong TA, Strawn LM, Sun L, Tang C, Hawtin R, Tang F, Shenoy N, Hirth KP, McMahon G, Cherrington: SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 1;60(15): 4152–4160, 2000 Shaheen RM, Davis DW, Liu W, Zebrowski BK, Wilson MR, Bucana CD, McConkey DJ, McMahon G, Ellis LM: Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res 1;59(21): 5412–5416, 1999 Borgstrom, P, Hillan, KJ, Sriramarao, P, Ferrara, N: Combination treatment with monoclonal anti-vascular endothelial growth factor antibody and doxorubicin reduces size of micro tumors of human breast carcinoma in vivo. 2000. (Genentech data) Borgstrom P, Hillan KJ, Sriramarao P, Ferrara N: Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res 56: 4032–4039, 1996 Gordon MS, Marjolin KA, Talpaz M: Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor antibody (rhuMAb VEGF) in patients with advanced cancer. (In Press) J Clin Oncol 2000 Marjolin KA, Gordon MS, Holmgren E, Gaudreault J, Novotny W, Fyfe G: Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advance cancer (submitted) Reese D, Frohlich D, Bok R, Corry M, Novotny W, Homgren E, Small E: A Phase II trial of humanized monoclonal antivascular endothelial growth factor antibody (rhuMAb VEGF) in hormone refractory prostate cancer (HRPC). (abstr) ASCO #1355, 1999 Reiser F, Way D, Bernas M, Witte M, Witte C: Inhibition of normal and experimental angiotumor endothelial cell proliferation and cell cycle progression by 2-methoxyestradiol. Proc Soc Exp Biol Med 219: 211–216, 1998 Schumacher G, Kataoka M, Roth JA, Mukhopadhyay T: Potent antitumor activity of 2-methoxyestradiol in human pancreatic cancer cell lines. Clin Cancer Res 5: 493–499, 1999 D'Amato RJ, Lin CM, Flynn E, Folkman J, Hamel E: 2-methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc Natl Acad Sci USA 91: 3964–3968, 1994 Hamel E, Lin CM, Flynn E, D'Amato RJ: Interactions of 2-methoxyestradiol, an endogenous mammalian metabolite, with unpolymerized tubulin and with tubulin polymers. Biochemistry 35: 1304–1310, 1996 Seegers JC, Lottering ML, Grobler CJ: The mammalian metabolite, 2-methoxyestradiol, affects p53 levels and apoptosis induction in transformed cells but not in normal cells. J Steroid Biochem Mol Biol 62: 253–267, 1997 Mukhopadhyaya T, Roth JA: Induction of apoptosis in human lung cancer cells after wild-type p53 activation by methoxyestradiol. Oncogene 14: 379–384, 1997 La Vallee TM, Hembrough WA, Papathanassiu A: 2-methoxyestradiol upregulates DR5 and induces apoptosis independently of p53 in endothelial and tumor cells. Clin Cancer Res 5(11 Suppl): 3745s, 1999 Attalla H, Makela TP, Adlercreutz H, Andersson LC: 2-methoxyestradiol arrests cells in mitosis without depolymerizing tubulin. Biochem Biophys Res Commun 228: 467–473, 1996 Schumacher G, Kataoka M, Roth JA, Mukhopadhyay T: Potent antitumor activity of 2-methoxyestradiol in human pancreatic cancer cell lines. Clin Cancer Res 5: 493–499, 1999 Fotsis T, Zhang Y, Pepper MS: The endogenous estrogen metabolite 2-methoxyestradiol inhibits angiogenesis and suppresses tumor growth. Nature 368: 237–239, 1994